SciTech Development is a clinical-stage, oncology-focused pharmaceutical company. Through innovative science and advanced nanotechnology, we’ve engineered ST-001 nanoFenretinide (ST-001)—a patented, new drug that combines a potent anticancer agent with a novel nanoparticle delivery system. ST-001 is now in clinical trials for T-cell non-Hodgkin lymphoma (T-cell NHL).  Exceptional preliminary data indicates successful drug delivery to targeted tissue, addresses dug bioavailability, reduces triglyceride toxicity, and has been proven safe to enhance therapeutic effectiveness. Guided by previous fenretinide studies, ST-001 may have potential across 15+ additional cancers—including lung, leukemia, head & neck, brain, ovarian, cervical, and pancreatic—either as a standalone therapy, a complementary agent, or in combination with chemotherapy to address critical unmet needs. The FDA has cleared a second IND, enabling our upcoming small-cell lung cancer (SCLC) trial. Our scalable drug development and nanomanufacturing is built to move ST-001 efficiently from lab to clinic. With $16M+ raised to date, we’re actively securing additional capital to accelerate development while deepening our commitment to innovation and strategic partnerships. Note: ST-001 is investigational and not yet FDA approved for commercial use.

SciTech Development, Inc.

Org chart

Teams

Offices